LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 32.28 | 770.25 | 2049 | 3392 | 0.6039 | 0.5799 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 32.28 | 770.25 | 2470 | 3392 | 0.7280 | 0.7242 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 34.50 | 770.25 | 2203 | 3712 | 0.5935 | 0.5891 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 34.50 | 770.25 | 2638 | 3712 | 0.7107 | 0.7205 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 36.73 | 770.25 | 2343 | 4086 | 0.5734 | 0.5874 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 36.73 | 770.25 | 2809 | 4086 | 0.6875 | 0.7117 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 38.95 | 770.25 | 2514 | 4543 | 0.5533 | 0.5872 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 38.95 | 770.25 | 3020 | 4543 | 0.6646 | 0.7051 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 41.17 | 770.25 | 2642 | 5010 | 0.5273 | 0.5781 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 41.17 | 770.25 | 3246 | 5010 | 0.6478 | 0.7031 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 43.39 | 770.25 | 2879 | 5404 | 0.5327 | 0.5985 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 43.39 | 770.25 | 3478 | 5404 | 0.6436 | 0.7097 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 45.61 | 770.25 | 2993 | 5813 | 0.5149 | 0.5928 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 45.61 | 770.25 | 3686 | 5813 | 0.6341 | 0.7107 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 47.83 | 770.25 | 3179 | 6223 | 0.5108 | 0.6005 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 47.83 | 770.25 | 3888 | 6223 | 0.6247 | 0.7110 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 50.05 | 770.25 | 3334 | 6629 | 0.5029 | 0.6029 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 50.05 | 770.25 | 4119 | 6629 | 0.6213 | 0.7158 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 52.27 | 770.25 | 3500 | 7058 | 0.4958 | 0.6058 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 52.27 | 770.25 | 4355 | 7058 | 0.6170 | 0.7195 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 54.49 | 770.25 | 3670 | 7555 | 0.4857 | 0.6063 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 54.49 | 770.25 | 4629 | 7555 | 0.6127 | 0.7236 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 56.71 | 770.25 | 3913 | 8001 | 0.4890 | 0.6182 | MN20160304_L02 | K22 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 56.71 | 770.25 | 4880 | 8001 | 0.6099 | 0.7276 | MN20160304_L02 | N04 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.1 | 58.94 | 770.25 | 4096 | 8444 | 0.4851 | 0.6221 | MN20160304_L02 | K22 |